In addition, COL22A1 was found to be overexpressed and to play a pro-oncogenic role in GBM, as demonstrated by impaired proliferation, migration, and invasion of glioma cells following COL22A1 silencing, underscoring its significance in tumor progression and as a biomarker for predicting patient survival (26). This evidence concerns the gene COL22A1 and glioma.